Public Health and Medical Professionals for Transparency Documents
Search:
File Name | Date Produced | File Size | Link |
---|---|---|---|
BATES-92_adc19ef-ve-cov-7pd2-wo-eval-sas.txt | November 17, 2021 | 9 KB | |
BATES-93_tv.xpt | November 17, 2021 | 16 KB | |
5.3.6 postmarketing experience.pdf | November 17, 2021 | 984 KB | |
5.2 tabular listing.pdf | November 17, 2021 | 2 MB | |
5.2 listing of clinical sites and cvs pages 1-41.pdf | November 17, 2021 | 8 MB | |
Pages 42-289-Section 5.2 – listing-clinical-sites-cvs_Part A.pdf | December 1, 2021 | 12 MB | |
Pages 42-289-Section 5.2 – listing-clinical-sites-cvs_Part B.pdf | December 1, 2021 | 14 MB | |
BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txt | December 13, 2021 | 9 KB | |
BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txt | December 13, 2021 | 9 KB | |
BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txt | December 13, 2021 | 9 KB | |
BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt | December 13, 2021 | 5 KB | |
BATES-FDA-CBER-2021-5683-0002377_supppr.xpt | December 13, 2021 | 72 KB | |
signed F21-5683 CBER Dec 13 2021 Response Letter.pdf | December 13, 2021 | 207 KB | |
BATES-FDA-CBER-2021-5683-0002378_ta.xpt | December 13, 2021 | 8 KB | |
BATES-FDA-CBER-2021-5683-0002379_te.xpt | December 13, 2021 | 3 KB | |
BATES-FDA-CBER-2021-5683-0002380_ti.xpt | December 13, 2021 | 37 KB | |
BATES-FDA-CBER-2021-5683-0002376_relrec.xpt | December 13, 2021 | 567 KB | |
CRFs for site 1055.pdf | December 13, 2021 | 6 MB | |
STN 125742_0_0 Section 2.5 Clinical Overview.pdf | December 13, 2021 | 4 MB | |
STN 125742_0_0 Section 2.7.3 Summary of Clinical Efficacy.pdf | December 13, 2021 | 3 MB | |
STN 125742_0_0 Section 2.7.4 summary-clin-safety.pdf | December 13, 2021 | 6 MB | |
Supplemental Index 12-22-21.pdf | December 22, 2021 | 2 MB | |
CRFs for site 1081.pdf | December 30, 2021 | 13 MB | |
CRFs for site 1096.pdf | January 18, 2022 | 11 MB | |
CRFs for site 1128.pdf | January 31, 2022 | 14 MB |
Pfizer’s Documents
http://phmpt.org/pfizers-documents
Court Documents
20 documents
File Name | Date Produced | File Size | Link |
---|---|---|---|
091621-Complaint.pdf | September 16, 2021 | 1 MB | |
111521-Second-Joint-Status-Report.pdf | November 15, 2021 | 382 KB | |
FDA Brief in Advance of Scheduling Conference.pdf | December 6, 2021 | 273 KB | |
FDA Appendix in Support.pdf | December 6, 2021 | 9 MB | |
Brief, Memorandum in Support filed by Public Health and Medical Professionals for Transparency re [21] Order Setting Deadline,Hearing.pdf | December 7, 2021 | 239 KB | |
Appendix in Support filed by Public Health and Medical Professionals for Transparency re [26] Brief, Memorandum in Support of Motion.pdf | December 7, 2021 | 16 MB | |
FDA’s Reply re Brief in Support of Motion.pdf | December 13, 2021 | 280 KB | |
FDA’s Appendix in Support of Brief.pdf | December 13, 2021 | 1 MB | |
REPLY filed by Public Health and Medical Professionals for Transparency re [22] Brief, Memorandum in Support of Motion.pdf | December 13, 2021 | 175 KB | |
Appendix in Support filed by Public Health and Medical Professionals for Transparency re [31] Reply.pdf | December 13, 2021 | 24 MB | |
ORDER_2022_01_06.pdf | January 6, 2022 | 169 KB | |
037 – Brief Memorandum in Support filed by FDA re [36] MOTION To Partially Modify Scheduling Order.pdf | January 18, 2022 | 247 KB | |
038 – Appendix in Support filed by FDA re [36] MOTION To Partially Modify Scheduling Order.pdf | January 18, 2022 | 1 MB | |
041 – Memorandum in Support filed by Pfizer, Inc. re [40] MOTION to Intervene for a Limited Purpose.pdf | January 21, 2022 | 1,014 KB | |
044 – PL PHPMT’S MOL IN OPPOSITION TO DEFENDANT’S MOTION TO MODIFY THE SCHEDULING ORDER OF THE COURT.pdf | January 24, 2022 | 420 KB | |
046 – RESPONSE filed by Food and Drug Administration re [40] MOTION to Intervene for a Limited Purpose.pdf | January 25, 2022 | 128 KB | |
047 – PLAINTIFF’S RESPONSE TO PFIZER INC.’S MOTION FOR LEAVE TO INTERVENE FOR A LIMITED PURPOSE.pdf | January 25, 2022 | 293 KB | |
056 – ORDER GRANTING IN PART THE MOTION TO MODIFY THE PRODUCTION SCHEDULE AND ADDOPTS THE JOINT STATUS REPORT MODIFIED AGREED PRODUCTION SCHEDULE.pdf | February 2, 2022 | 124 KB | |
Order February 7, 2022.pdf | February 7, 2022 | 151 KB | |
034 – Transcript of Scheduling Conference (December 14, 2021).pdf | March 16, 2022 | 141 KB |
20 documents
https://phmpt.org/media-inquiries
Um höfund
- Sigurlaug Ragnarsdóttir
- ✞༺(((( Ⓒilla ℜągnąℜṧ )))༻♚༺ BA Classical Art Historian || MA Culture & Media || Tourism & Sales Management || Web Design || Photo & Videographer for Tourism Magasins ༻
Síðustu færslur
- MANNRÉTTINDI19. nóvember, 2024MENNTASPJALL VALGERÐAR SNÆLAND JÓNSDÓTTUR
- Sigurlaug Ragnarsdóttir15. ágúst, 2024‘Really Chilling’: Five Countries to Test European Vaccination Card
- MANNRÉTTINDI9. ágúst, 2024Lög um borgaralega handtöku voru felld úr gildi árið 2008
- Óflokkað30. maí, 2024GLÚMUR SEGIR ARNAR ÞÓR VERA MEÐ VITLAUSAR SKOÐANIR
- 525 Posts
- 0 Comments
✞༺(((( Ⓒilla ℜągnąℜṧ )))༻♚༺ BA Classical Art Historian || MA Culture & Media || Tourism & Sales Management || Web Design || Photo & Videographer for Tourism Magasins ༻